Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

Pfizer will be gaining exclusive rights to 3SBio’s investigational PD-1 and VEGF-targeted bispecific antibody in a deal worth over $6bn. The candidate, SSGJ-707, is currently being evaluated in ...

The pharmaceutical giant will pay biotechnology company 3SBio $1.25 billion upfront for rights outside of China to a therapy dubbed SSGJ-707. 3SBio, which is based in Shenyang, China, could receive up ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Meanwhile, 3SBio is gearing up to initiate the first Phase 3 study in China in 2025. Pfizer Oncology, known for its extensive portfolio and pipeline, aims to deliver transformative therapies for ...